Dr Reddy’s (NYSE: RDY) Europe head reports 8,450 ADR-backed shares
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
DR REDDYS LABORATORIES LTD executive Patrick Rudolf Aghanian, Head - Europe Generics, filed an initial insider ownership report. The filing shows direct beneficial ownership of 8,450 Equity Shares underlying ADRs, with no reported purchases or sales associated with this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
AGHANIAN PATRICK RUDOLF
Role
Head - Europe Generics
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Equity Shares underlying ADRs | -- | -- | -- |
Holdings After Transaction:
Equity Shares underlying ADRs — 8,450 shares (Direct)
Footnotes (1)
Key Figures
Equity shares owned: 8,450 Equity Shares underlying ADRs
1 metrics
Equity shares owned
8,450 Equity Shares underlying ADRs
Direct beneficial ownership reported on Form 3
Key Terms
Form 3, Equity Shares underlying ADRs, beneficial ownership
3 terms
Form 3 regulatory
"filed an initial insider ownership report"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership financial
"serving as an initial statement of beneficial ownership"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What does the DR REDDYS (RDY) Form 3 filing disclose for Patrick Rudolf Aghanian?
The Form 3 shows that Patrick Rudolf Aghanian, Head - Europe Generics, directly holds 8,450 Equity Shares underlying ADRs of DR REDDYS LABORATORIES LTD. It is an initial ownership report, not a record of new share purchases or sales.
Is the RDY Form 3 filing reporting a new insider trade by Patrick Rudolf Aghanian?
No, the RDY Form 3 does not report a new trade. It records Patrick Rudolf Aghanian’s existing direct ownership of 8,450 Equity Shares underlying ADRs, serving as an initial statement of beneficial ownership rather than a buy or sell transaction.
What type of security is reported in the DR REDDYS (RDY) Form 3 for Patrick Rudolf Aghanian?
The Form 3 lists Equity Shares underlying ADRs as the security held by Patrick Rudolf Aghanian. These represent the underlying equity shares associated with American Depositary Receipts, reported here as his direct beneficial ownership stake in DR REDDYS LABORATORIES LTD.
Does the DR REDDYS (RDY) Form 3 indicate whether the holdings are direct or indirect?
Yes. The filing labels the 8,450 Equity Shares underlying ADRs as direct ownership, using an ownership code of “D”. There is no indication of indirect holdings through entities like trusts or partnerships in the provided data.